Clinical Trial Update: Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease in Hemodialysis Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating atorvastatin for slowing the progression of cardiovascular disease in patients undergoing hemodialysis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Cardiovascular Disease
• Dyslipidemia
• End-stage Renal Disease
• Vascular Calcification

Drugs mentioned

• atorvastatin (atorvastatin)

Snippet

Sponsor: Ercan OK | Conditions: Vascular Calcification, Atherosclerosis | Phase 3 | Status: COMPLETED